
News|Articles|November 1, 2010
Formulary Digital Edition November 2010
Attention deficit hyperactivity disorder: More than a child's disorder; Focus on lurasidone; Agents in late-stage development for the treatment of multiple sclerosis
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Immunotherapy combination of teclistamab and daratumumab heralded as potential 'functional cure' for multiple myeloma | ASH 2025
2
The trend toward post-infusion outpatient care of patients treated with CAR-T | ASH 2025
3
2025 FDA dermatology approvals: A new gene therapy and two targeted therapies
4
Sanofi’s Qfitlia seems favorable for hemophilia with easier dosing and broad coverage | ASH 2025
5





















































